
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. has demonstrated robust financial performance, reporting a revenue of $8.8 million in the second quarter, reflecting a remarkable year-over-year increase of 95% and an 18% sequential growth. The company is on track to achieve continued revenue growth across its various streams, with projections indicating an increase to $43 million in total revenue by FY26, fueled by rising system sales and catheter utilization. Additionally, regulatory advancements for new products, such as the MAGiC ablation catheter and the MAGiC Sweep mapping catheter, position Stereotaxis to leverage its innovative portfolio and drive further expansion in the robotic interventional market.
Bears say
Stereotaxis Inc has reported operating expenses of $8.6 million, with adjusted expenses decreasing to $6.0 million from $6.8 million in the previous year, indicating a decline but still reflecting high operational costs. Notable concerns affecting the company’s outlook include delays in product approvals, ongoing supply issues, changes in reimbursement rates, and competitive pressures from both manual and robotic systems, all of which could significantly impact revenue expectations. Additionally, with a net loss of $3.8 million and a limited cash runway of two years, Stereotaxis may need to secure further financing to maintain its operations and sales expansion, raising further uncertainties about its financial stability.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares